![](https://investorshub.advfn.com/uicon/77609.png?cb=1485869477)
Saturday, August 10, 2024 5:27:38 AM
Friday, August 09, 2024
367 Notice Setting or Resetting Hearing on Motion Fri 08/09 9:15 AM
ELECTRONIC NOTICE Setting Hearing on Motion296 MOTION to Compel Defendant Pfizer Inc. to Produce Documents and Provide Deposition Testimony : Motion Hearing set for September 25, 2024 at 11:30 AM in Courtroom 14 (In person only) before Magistrate Judge Jennifer C. Boal. Plaintiff Enanta Pharmaceuticals, Inc. has filed a motion to, among other things, compel Pfizer to produce an April 6, 2022 email as well as the attachments to that email. Docket No. 296. Defendant Pfizer, Inc. maintains that the email is privileged and has offered to submit the email ex parte for in camera review. See Docket No. 334 at 17. No later than August 22, 2024, Pfizer shall submit the email and attachments for in camera review. The documents must be submitted in hard copy at the Clerk's Office and marked DO NOT DOCKET, SUBMITTED FOR IN CAMERA REVIEW. (Hutchins, Aaron)
https://www.pacermonitor.com/public/case/44980990/Enanta_Pharmaceuticals,_Inc_v_Pfizer_Inc
Inch by inch, we're getting there -
Barbara A. Fiacco - ENTA's Attorney - additional info -
She has represented leading pharmaceutical and life sciences clients in significant patent infringement lawsuits that have resulted in summary judgment or other favorable outcomes for her clients. Barbara also represents these clients in trade secret, inventorship, and technology transfer disputes as well as other commercial litigation.
Barbara is a Past President of the American Intellectual Property Law Association (AIPLA) and a Past President of the United States section of the International Association for the Protection of Intellectual Property (AIPPI-US), serving from 2019 to 2020. She has held a number of leadership roles in AIPLA and has represented this premier intellectual property law association in testimony on behalf of AIPLA before the Senate Judiciary Committee’s Subcommittee on Intellectual Property as well as in amicus briefs to the Supreme Court.
https://foleyhoag.com/people/fiacco-barbara/
Recent ENTA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 09:24:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:05:10 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter • Business Wire • 08/05/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 09:29:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 09:30:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 12:38:39 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 08:15:05 PM
- Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:37:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:00:34 PM
- Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference • Business Wire • 05/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:05:14 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET • Business Wire • 05/06/2024 08:01:00 PM
- Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/30/2024 11:10:00 AM
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer • Business Wire • 04/30/2024 11:00:00 AM
- Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 • Business Wire • 04/29/2024 11:00:00 AM
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 • Business Wire • 04/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:12:41 PM
- Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference • Business Wire • 03/06/2024 12:00:00 PM
Kona Gold Beverages, Inc. Nears Completion of Reverse Merger with New Candidate • KGKG • Aug 12, 2024 10:00 AM
Maybacks Global Entertainment and DigiTrax Entertainment Sign Agreement to Broadcast "Karaoke Cloud" on iDreamCTV • AHRO • Aug 12, 2024 8:45 AM
HealthLynked Partners with RxSpark to Enhance Medication Access and Management for Patients • HLYK • Aug 12, 2024 8:00 AM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM